Covered by insurance in all 50 states, incl. Medicare Advantage day one
Siggy
Back to Blog

Antidepressants and Pregnancy: What the Latest Evidence Shows

Clinically reviewed by Daniel Montville, MD

Reviewed November 5, 2026 · Last updated November 5, 2026

Key Takeaways

  • A July 2025 FDA expert panel raised concerns about SSRIs in pregnancy, and ACOG called it alarmingly unbalanced because only one of 10 panelists spoke to the importance of treatment.
  • In a study of nearly 950,000 pregnancies, SSRIs showed no substantial increase in heart defects once researchers accounted for depression itself.
  • A 2026 meta-analysis of 37 studies found small links between prenatal antidepressants and autism or ADHD that weakened or disappeared after adjusting for family and mental health factors.
  • Stopping antidepressants carries its own risk. A 2026 study of 6,552 patients found a 14% higher relative risk of postpartum depression among those who stopped compared with those who continued.

You’re pregnant, or hoping to be, and the antidepressant you take finally has you feeling like yourself. Then the headlines say it might hurt your baby. Here’s what makes this question hard: your mental health and your baby’s development are linked. A 2026 JAMA Psychiatry review notes that maternal stress and psychiatric illness can themselves affect fetal and infant outcomes. Weighing medication risk takes precision, because you have to separate the effect of the drug from the effect of the depression it treats.

Obstetric guidance on this question is clear. ACOG’s 2023 guideline recommends SSRIs as first-line medication for perinatal depression and anxiety. A 2014 NEJM study of 949,504 pregnancies found no substantial increase in heart defects from SSRIs once depression itself was accounted for. The reassurance is real, and the science behind it is well established.

But a reassuring guideline doesn’t help much when a federal panel tells you to be afraid, and at Siggy we’d rather walk you through the actual numbers than ask you to pick a side.

This guide covers what the July 2025 FDA panel said, what new 2026 research adds, which risks are real but small, and what stopping treatment can cost. The decision belongs to you and your care team, and it should rest on evidence you can see for yourself.

What This Page Covers

What Did the 2025 FDA Panel Say?

On July 21, 2025, an FDA expert panel met to discuss SSRIs and pregnancy. Several panelists raised concerns about fetal risks and discussed stronger warnings.

The response from obstetricians was fast. In a statement from ACOG, the American College of Obstetricians and Gynecologists called the panel alarmingly unbalanced, noting that only one of 10 experts spoke to the importance of SSRIs as a tool for treating perinatal anxiety and depression. ACOG said robust evidence shows SSRIs are safe in pregnancy and that most don’t increase the risk of birth defects. It also agreed with one panel point: randomized trials on SSRI safety in pregnancy should be prioritized.

A panel discussion isn’t a labeling decision. If you want to know what the current label says for your specific medication, ask your prescriber or pharmacist.

Do SSRIs Cause Birth Defects?

The best evidence says no substantial increase. In the New England Journal of Medicine study, 6.8% of the 949,504 women used an antidepressant in the first trimester. Before adjustment, heart defects appeared in 90.1 per 10,000 exposed infants versus 72.3 per 10,000 unexposed. Once the researchers limited the comparison to women with depression and adjusted for its severity, the relative risk for SSRIs dropped to 1.06, which wasn’t statistically significant.

That shift shows why early studies were alarming. They often compared people taking SSRIs with people who didn’t have depression at all, so the effects of the illness got blamed on the medicine. The same study found no significant link between paroxetine and a heart outflow defect, or between sertraline and septal defects, two pairings that had worried clinicians.

What About Autism and ADHD?

This is the fear that hits hardest, and 2026 brought the clearest answer yet. A Lancet Psychiatry meta-analysis pooled 37 studies covering 648,626 antidepressant-exposed pregnancies and nearly 25 million unexposed ones.

The raw numbers showed modest associations with ADHD and autism. But similar associations showed up when mothers took antidepressants only before conception, and when fathers took them during pregnancy, even though a father’s medication doesn’t reach the fetus. That pattern points to shared family and genetic factors rather than the drug. After adjusting for maternal mental health and family influences, the associations weakened or disappeared, and no significant link remained for specific SSRIs or SNRIs. The authors rated the certainty of evidence as low to very low and concluded that treatment should be continued for pregnant women with moderate to severe depression.

Which Risks Are Real?

Honest counseling means naming the risks that hold up. The clearest one is persistent pulmonary hypertension of the newborn (PPHN), a condition where a baby’s lung blood pressure stays high after birth. A BMJ PPHN meta-analysis found no link with SSRI use in early pregnancy but a higher risk with late-pregnancy use. In absolute terms, that was about 2.9 to 3.5 extra cases per 1,000 infants, meaning roughly 286 to 351 women would need to take an SSRI late in pregnancy for one additional case. The authors called the absolute risk low.

Here’s how the main concerns stack up against the research covered in this guide.

Concern What Large Studies Found Key Number
Heart defects No substantial increase after accounting for depression Adjusted relative risk 1.06, not significant
Autism and ADHD Small links that weaken after accounting for family factors 37 studies, 648,626 exposed pregnancies
PPHN in newborns Small increase with late-pregnancy use About 3 extra cases per 1,000
Postpartum depression Higher risk when antidepressants are stopped 14% higher relative risk

Let your delivery team know about any medication you take, so they can watch your baby closely in the first days.

What Does Untreated Depression Cost?

Leaving depression untreated isn’t a neutral choice. ACOG’s statement lists the risks of untreated depression in pregnancy: substance use, preterm birth, preeclampsia, low birth weight, less engagement in prenatal care and self-care, impaired attachment with the baby, and suicide. ACOG adds that mental health conditions are the most frequent cause of pregnancy-related death. The 2026 JAMA Psychiatry review calls psychiatric conditions a leading cause of maternal illness and death and says major depression must be treated during pregnancy to protect mother and baby.

Stopping medication has measurable consequences too. A large 2026 cohort study of 6,552 patients with depression found that 37.7% developed postpartum depression. Compared with continuing, stopping antidepressants during pregnancy carried a 14% higher relative risk. For people who still had depressive symptoms early in pregnancy and stopped their medication, the risk was 2.72 times that of people who continued with few or no symptoms.

“Suffering with insomnia and depressive thoughts for months makes life miserable.” That’s true in pregnancy too, and it matters for you and your baby. Our guide to depression during pregnancy covers the signs to watch for.

Planning a Pregnancy or Already Pregnant?

ACOG recommends against withholding or stopping mental health medication because of pregnancy or breastfeeding alone. The right plan depends on you, and these steps help:

  • Don’t stop or cut your dose suddenly. Talk with your prescriber and OB first.
  • Review your history, including how severe past episodes were and what happened when you stopped before.
  • Share your current symptoms honestly, since symptom severity in pregnancy can guide the decision.
  • Ask whether therapy should be part of your plan alongside or instead of medication.
  • Plan for the postpartum months, since postpartum depression affects about 1 in 7 women in the U.S.

The 2026 JAMA Psychiatry review recommends a structured decision process that weighs untreated illness, treatment benefits, and medication exposure together. You deserve that full conversation, and no one should rush you through it.

Is It Safe to Breastfeed on an Antidepressant?

For most people, yes. According to NIH’s LactMed database, sertraline passes into breast milk at low levels and is usually undetectable in the infant’s blood. No adverse effects on development have been found in infants followed up to age 5, and most expert reviewers consider sertraline a preferred antidepressant during breastfeeding. LactMed also notes that people taking an SSRI may have more difficulty breastfeeding and may benefit from extra lactation support.

For what comes after delivery, our guide on how long postpartum depression lasts walks through the timeline.

This article is for education only and isn’t a substitute for personal medical advice. Never stop or change a medication without talking to your prescriber. It reflects sources available as of October 2026. If you’re having thoughts of suicide or harming yourself, call or text 988, or call 911 in an emergency.

Make This Decision With Support Instead of Fear

“I feel like some doctors do not take me seriously.” When you’re scared about your baby and your own mental health at the same time, being heard matters. Start your anonymous intake with Siggy to describe your mood, your anxiety, and the medications you take, in your own words. It’s free, asks for no name or email, and gives you a downloadable summary you can bring to your OB or prenatal care team. Siggy’s licensed prescribers diagnose and treat the full range of mental health conditions, including perinatal anxiety and depression, and a licensed prescriber reviews your full clinical picture before anything is prescribed.

Mental healthcare should stay with you between appointments.

Siggy combines daily check-ins with clinician-supervised care so your treatment plan can respond to what is actually happening.

Start anonymously. A real doctor reviews every clinical decision. HIPAA-compliant.

Start Anonymous Intake

Frequently Asked Questions

Is it safe to take antidepressants while pregnant?

For many people, yes, after an individualized discussion with a prescriber. ACOG's 2023 guideline recommends SSRIs as first-line medication for perinatal depression and anxiety, and a 2026 JAMA Psychiatry review concluded that SSRIs carry little or no risk of serious harm once their effects are separated from those of depression. Small risks remain, such as a slightly higher chance of a newborn lung condition with late-pregnancy use, so the decision should weigh those against the risks of untreated depression.

Do SSRIs cause autism?

Current evidence doesn't show that SSRIs cause autism. A 2026 meta-analysis of 37 studies found a small raw association, but it weakened or disappeared after accounting for maternal mental health and family factors. Fathers' antidepressant use showed a similar association, which points to shared family factors rather than the drug. No significant link remained for specific SSRIs once confounding was minimized.

Should I stop my antidepressant when I find out I'm pregnant?

Don't stop on your own. Talk with your prescriber and OB first. ACOG recommends against discontinuing mental health medications just because of pregnancy, and a 2026 study found that stopping antidepressants during pregnancy was linked to a higher risk of postpartum depression, especially for people who still had depressive symptoms.

Which antidepressant is safest during pregnancy?

There's no single safest choice for everyone. ACOG recommends SSRIs as the first-line medication class, and the right option depends on your history, what has worked for you, and whether you plan to breastfeed. For people who haven't taken a mood medication before, the guideline names sertraline and escitalopram as first-line choices. A large U.S. study found no significant link between paroxetine and a specific heart defect or between sertraline and septal defects after adjusting for depression.

Can I breastfeed while taking sertraline?

Most people can. According to the NIH LactMed database, sertraline passes into breast milk at low levels, is usually undetectable in the infant's blood, and has shown no adverse developmental effects in infants followed up to age 5. Most expert reviewers consider it a preferred antidepressant during breastfeeding.

Did the FDA add a pregnancy warning to SSRIs after the 2025 panel?

The July 2025 FDA expert panel discussed stronger warnings, but a panel discussion isn't the same as a labeling decision. Because labeling can change, ask your prescriber or pharmacist about the current label for your specific medication. Major medical societies, including ACOG, continue to support SSRI treatment when it's clinically appropriate.

Sources

  1. Wisner KL, Oberlander TF, Osborne LM, Huybrechts KF. Depression and SSRI treatment during pregnancy: prioritizing maternal mental health. JAMA Psychiatry. Published online August 12, 2026. doi:10.1001/jamapsychiatry.2026.2405
  2. American College of Obstetricians and Gynecologists. Clinical Practice Guideline No. 5: Treatment and management of mental health conditions during pregnancy and postpartum. Obstetrics & Gynecology. 2023;141(6):1262-1288. doi:10.1097/AOG.0000000000005202
  3. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. New England Journal of Medicine. 2014;370(25):2397-2407. doi:10.1056/NEJMoa1312828
  4. U.S. Food and Drug Administration. FDA Expert Panel on Selective Serotonin Reuptake Inhibitors (SSRIs) and Pregnancy. July 21, 2025. fda.gov
  5. American College of Obstetricians and Gynecologists. ACOG Statement on the Benefit of Access to SSRIs During Pregnancy. July 21, 2025. acog.org
  6. Chan JKN, Zhong AHF, Lam JYH, et al. Maternal and paternal antidepressant use before and during pregnancy and offspring risk of neurodevelopmental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2026;13(6):472-484. doi:10.1016/S2215-0366(26)00089-1
  7. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014;348:f6932. doi:10.1136/bmj.f6932
  8. Ridout KK, Eswarappa C, Alavi M, et al. Antidepressant continuation in pregnancy and postpartum depression risk across racial and ethnic groups. American Journal of Obstetrics and Gynecology. Published online July 31, 2026. doi:10.1016/j.ajog.2026.07.031
  9. National Institute of Child Health and Human Development. Sertraline. Drugs and Lactation Database (LactMed). Revised August 2026. ncbi.nlm.nih.gov